Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

A-H Premium Weekly: Asymchem Lab, Shanghai Junshi, Great Wall Motor

A-H Premium Weekly: Cansino, Great Wall Motor, Shandong Xinhua

A-H Premium Weekly: Remegen, CNOOC, COSCO Shipping

A-H Premium Weekly: CICC, Great Wall Motor, Cansino

A-H Premium Weekly: Asymchem Lab, China Comm Construction

A-H Premium Weekly: China Southern, Shanghai Junshi, Shanghai Haohai, Shanghai Fudan

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyse the changes of A/H premium on 139 stocks over the last week. </li>
<li>Health care, consumer discretionary, and energy led the week on week A-H premium increase of 3.8ppt. </li>
<li>We highlight A-H premium increases in CICC, Great Wall Motor, and Cansino Biologics.</li>
</ul>


We analyse the changes of A/H premium on 139 stocks over the last week. 
Health care, consumer discretionary, and energy led the week on week A-H premium increase of 3.8ppt. 
We highlight A-H premium increases in CICC, Great Wall Motor, and Cansino Biologics.


China International Capital Corporation (3908 HK)